None listed
Conditions
Brief summary
Tiotropium (Spiriva) and formoterol (Oxis) are both currently available prescription medicines for people with COPD. Each of them has a particular effect on the airway. They are usually prescribed independently although it is quite possible for them to be prescribed together. Therefore some people with COPD may already be taking one or both of them. People participating in this study will take a regular dose of tiotropium plus a placebo for 6 weeks and a regular dose of tiotropium plus formoterol for 6 weeks. There will be 2 weeks between each 6 week period when participants will take only tiotropium.
Interventions
At the initial visit all subjects will be commenced on Tiotropium 18mcg daily via inhaler. Subjects will be randomised to receive either placebo or formoterol 12mcg bd via inhaler for 6 weeks. There will then be a 2 week washout period for formoterol (not Tiotropium). Subjects will then crossover to the alternate arm of therapy for a further 6 weeks.
Sponsors
Centre for Clinical Research and effective practice (CCRep)
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used)
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Chronic Obstructive Airways Disease (COPD).
Exclusion criteria
Myocardial infarction within 3 months of enrolment in the study. Prostatism Glaucoma
Outcome results
None listed